Abstract: Disclosed are: a polypeptide marker for diagnosing arteriosclerosis; a gene marker for diagnosing arteriosclerosis; an antibody; a probe for detecting an arteriosclerosis marker gene; a DNA microarray or a DNA chip for detecting an arteriosclerosis marker gene; a method for detecting arteriosclerosis; and a kit for diagnosing arteriosclerosis; with which an arteriosclerotic lesion can be detected with much improved accuracy.
Abstract: The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells.
Abstract: The present invention provides methods, devices and test kits for rapid detection and identification of one or more live target microorganisms in a liquid sample or grown on plates containing solid nutrient media. The invention includes mixing the one or more target microorganisms with one or more aptamers and/or one or more antibodies, each conjugated to a reporter compound and specific for a first site on the one or more target microorganisms to form a mixture. The mixture is placed on a permeable membrane having immobilized thereon one or more aptamers linked to an amine compound, and/or one or more antibodies, each specific for a second site on the one or more target microorganisms or a site on the aptamer conjugate and/or antibody conjugate. A detection solution is added to the membrane, and detection and identification of the one or more target microorganisms is achieved in less than one hour.
Abstract: Luminescence assays and compositions for assay of biomolecular interaction and activity and detection of modulators of biomolecular interaction and activity are provided. Technology described herein has utility in a variety of assay formats and types, for example, simultaneous monitoring multiple parameters which affect interaction and activity of biological molecules. Compositions and methods are provided herein which include a first solid-phase support associated with a first specific binding agent and a photosensitizer; a second solid-phase support associated with a second specific binding agent and a first emission system; and a third solid-phase support associated with a third specific binding agent and a second emission system.
Type:
Grant
Filed:
February 22, 2010
Date of Patent:
July 16, 2013
Assignee:
PerkinElmer BioSignal, Inc.
Inventors:
Philippe Roby, Roger Bosse, Mathieu Arcand
Abstract: A microfluidic-based flow assay and methods of manufacturing the same are provided. Specifically, the microfluidic flow assay includes a micropatterned surface that induces clot formation and an array of microfluidic channels though which blood flows. The micropatterned surface contains two clotting stimuli, one for inducing platelet adhesion and another for inducing the coagulation cascade.
Abstract: An isolated protein which is at least partially encoded by a polynucleotide sequence encoding a novel sulfotransferase is provided together with a composition which includes the isolated protein. A transgenic organism transformed by a polynucleotide encoding a protein which is at least partially encoded by a novel sulfotransferase is also provided. The invention also includes a process for in-vivo and in-vitro making a sulfated polysaccharide from an unsulfated polysaccharide or increasing the sulfur content of an already sulfated polysaccharide.
Type:
Application
Filed:
April 11, 2011
Publication date:
July 11, 2013
Inventors:
Shoshana Arad, Lena Plesser, Yaakov Weinstein
Abstract: The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens.
Type:
Application
Filed:
December 21, 2012
Publication date:
July 11, 2013
Applicant:
Inserm (Institut National de la Sante et de la Recherche Medicale)
Abstract: Disclosed is a means for improving the clinical outcomes of cancer therapy. Specifically disclosed is an activity potentiator comprising a compound capable of inhibiting the expression of RFP (RET finger protein) gene or the activity of RFP as an active ingredient. The activity of an anti-cancer agent having an oxidative stress inducing ability can be potentiated by using the anti-cancer agent in combination with the activity potentiator. Further specifically disclosed are a biomarker useful for the recognition of prognosis in a cancer patient and use of the biomarker.
Type:
Application
Filed:
December 27, 2012
Publication date:
July 11, 2013
Applicant:
NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
Inventor:
National University Corporation Nagoya University
Abstract: Evaluation of VLP-I levels in combination with at least one of amyloid-? peptide (AB), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.
Type:
Grant
Filed:
August 21, 2008
Date of Patent:
July 9, 2013
Assignee:
Washington University
Inventors:
Jack H. Ladenson, Omar Laterza, Vijay Modur
Abstract: The present invention provides a method and kit for detection of two or more target molecules in a single tissue sample, such as for gene and protein dual detection in a single tissue sample. Methods comprise treating a tissue sample with a first binding moiety that specifically binds a first target molecule. Methods further comprise treating the tissue sample with a solution containing a soluble electron-rich aromatic compound prior to or concomitantly with contacting the tissue sample with a hapten-labeled binding moiety and detecting a second target molecule. In one example, the first target molecule is a protein and the second is a nucleic acid sequence, the first target molecule being detected by immunohistochemistry and the second by in situ hybridization. The disclosed method reduces background due to non-specific binding of the hapten-labeled specific binding moiety to an insoluble electron rich compound deposited near the first target molecule.
Type:
Grant
Filed:
August 21, 2009
Date of Patent:
July 9, 2013
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Richard Gniewek, Michael Farrell, Hiroaki Nitta, Megan Lehrkamp, Jerome Kosmeder, Brian Daniel Kelly, Thomas Grogan, Fabien Gaire, Mary Padilla, Christopher Bieniarz
Abstract: A modified porous membrane comprising a polymer coating grafted to a porous membrane is described. The polymer coatings grafted to the porous membranes generally comprise a polymer of variable length of an electron beam (e-beam) reactive moiety, designated “poly-(A)x,” a linkage group that forms a bond between the between the poly-(A)x, and a functional B group available to react with a chemical group on a biomolecule, wherein the polymer coating on the porous membrane facilitates the immobilization of a biomolecule, such as DNA, RNA, a protein, and an antibody, on the porous membrane. The compositions find use in immunoassays, in vitro diagnostic tests, point of care tests, techniques for the isolation of a biomolecule from a biological sample, and other methods that require the immobilization of a biomolecule on a porous membrane. Methods of making these modified porous membranes are also disclosed.
Type:
Application
Filed:
December 29, 2011
Publication date:
July 4, 2013
Applicant:
GENERAL ELECTRIC COMPANY
Inventors:
Bing Li, Cathryn Ellen Olsen, David Roger Moore
Abstract: A modified porous membrane comprising a polymeric hydrophilic coating bonded to a porous membrane is described. The polymeric hydrophilic coatings grafted to the porous membranes comprise, for example, a PEG moiety such as a PEGMA, a PEGDA, or a TMPET, wherein the polymeric hydrophilic coating on the porous membrane decreases non-specific binding of unwanted material to the porous membrane and increases the signal to noise ratio in immunoassays, in vitro diagnostic tests, and point of care tests. Methods of making these modified porous membranes are also disclosed.
Abstract: The present invention provides a method comprising allowing a reaction of a sample, a reagent containing Factor C, which can be activated by binding with endotoxin, and a synthetic luminescent substrate comprising a luminescent substrate bound to a peptide, for release of the luminescent substrate from the synthetic luminescent substrate, allowing a luminescent enzyme to act on the luminescent substrate released in the luminescent substrate release step, for measurement of the luminescence intensity, and quantifying the level of endotoxin in the sample based on a measured value obtained in the luminescence measuring step, the method enabling endotoxin to be simply and quickly measured at a level that cannot be detected in conventional methods for endotoxin measurement, without use of any dedicated measuring device.
Abstract: The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-?) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related disorders. In addition, the present invention provides methods for optimizing vaccine schedules and compositions, thereby preventing or reducing the risks of vaccine-induced inflammatory and/or autoimmune-related disorders.
Type:
Application
Filed:
June 30, 2011
Publication date:
June 27, 2013
Applicant:
UNIVERSITY OF SOUTH FLORIDA
Inventors:
Jun Tan, Demian Obregon, Antoinette Bailey
Abstract: Described are assay methods, modules and kits useful in the detection, treatment and/or prevention of dementia and related conditions, including but not limited to Alzheimer's disease and mild cognitive disorders.
Abstract: The present invention relates to a reliable method of prediction of infectious peritonitis in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum or plasma, and a high level is indicative of the development and the severity of peritonitis, allowing the classification of patients according to risk.
Type:
Application
Filed:
August 30, 2011
Publication date:
June 27, 2013
Applicant:
Universitaet Zuerich
Inventors:
Walter Halangk, Rolf Graf, Raphael Gukasjan, Hans-Ulrich Schulz
Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
Type:
Application
Filed:
August 7, 2012
Publication date:
June 27, 2013
Applicants:
Genentech, Inc., AC Immune S.A.
Inventors:
Andrea Pfeifer, Maria Pihtgren, Andreas Muhs, Ryan Watts
Abstract: Described herein are systems and methods for extending the dynamic range of assay methods and systems used for determining the concentration of analyte molecules or particles in a fluid sample. In some embodiments, a method comprises spatially segregating a plurality of analyte molecules in a fluid sample into a plurality of locations. At least a portion of the locations may be addressed to determine the percentage of said locations containing at least one analyte molecule. Based at least in part on the percentage, a measure of the concentration of analyte molecules in the fluid sample may be determined using an analog, intensity-based detection/analysis method/system and/or a digital detection/analysis method/system. In some cases, the assay may comprise the use of a plurality of capture objects.
Abstract: Use of an animal model of spontaneous metastasis bearing a tumor derived from a cell line RM72 (Accession No. NITE BP-1110) allows simultaneous evaluation of tumorigenesis and spontaneous cancer metastasis. Use of a screening method using the animal model of spontaneous metastasis allows the obtainment of a substance having an anticancer activity and/or an anti-metastatic activity. Use of another screening method for selecting a substance that increases the expression of RECK in a cancer cell allows the obtainment of a substance that can serve as an active ingredient in an anticancer drug.
Type:
Application
Filed:
July 29, 2011
Publication date:
June 27, 2013
Inventors:
Makoto Noda, Ryuya Murai, Hitoshi Kitayama, Yoko Yoshida
Abstract: The present invention relates to the newly identified timerization initiating and stagger determining capacity of the NC2 domain of collagen IX. The invention further relates to a hexavalent molecular building block wherein the linkage of additional moieties to the amino and carboxyl terminals of monomers comprising the NC2 domain of collagen IX promotes the directed association of those moieties via the trimerization initiating and stagger determining capacity of the NC2 domain of collagen IX.
Abstract: The present invention relates to a method of identifying a compound involved in pain, the use of Car3 nucleic acid or Car3 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.
Type:
Application
Filed:
January 20, 2011
Publication date:
June 20, 2013
Applicant:
SANOFI
Inventors:
Mathias Gebauer, Martin Michaelis, Danping Ding-Pfennigdorff, Anke M. Schulte, Daniel Ziemek, Christiane Metz-Weidmann
Abstract: The invention provides methods for reducing diabetes susceptibility in a subject and methods for increasing the expression of LL or CLORF32 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ll RNA or Clorf32 RNA comprising contacting a cell with an agent; determining expression of the Ll RNA or Clorf32 RNA in the presence and the absence of the agent; and comparing expression of the Ll RNA or Clorf32 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ll RNA or Clorf32 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.
Type:
Application
Filed:
December 12, 2008
Publication date:
June 20, 2013
Applicant:
The Trustees of Columbia University in the City of New York
Inventors:
Rudolph L. Leibel, Wendy K. Chung, Charles LeDuc, Stuart G. Fischer, Chouinard Roland
Abstract: The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for hematopoietic growth factor inducible neurokinin-1 (HGFIN), wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of renal injury or renal disease, and/or the rate of loss of renal function. In other embodiments, the invention provides a method of detecting an indicator of systemic inflammation. This method entails assaying a biological sample for HGFIN, wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of systemic inflammation. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.
Type:
Grant
Filed:
November 5, 2009
Date of Patent:
June 11, 2013
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Inventors:
Sharon Adler, Tiane Dai, Ying Wang, Mukti Patel-Chamberlin, Cynthia C. Nast, Janine LaPage, Nosratolah Dabir Vaziri, Madeleine V. Pahl
Abstract: The present invention relates to MST1 and MST2 cancer biomarkers. The inventors demonstrate herein that MST1 and/or MST2 can be used as biomarkers for the detection and prognosis of prostate cancer. The invention further discloses that enforced expression of MST1 can be used to inhibit and/or suppress the progression of prostate cancer.
Abstract: This invention provides a sample analyzing device and sample analyzing method designed to suppress nonuniform capture of magnetic particles (10) and detect a desired substance with higher accuracy.
Abstract: The present invention relates to an assay device and a method for using such for the quantitative determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains a test site having immobilized thereon a ligand capable of reacting with the analyte and binding such to the test site, and two standard band sites having immobilized thereon known high and low concentrations of a calibrator agent capable of reacting with a label conjugate and binding such to the standard sites, wherein the upstream membrane has a site for the application of a sample to be analyzed, and has a site downstream from the sample application site for depositing label conjugates capable of reacting with the analyte and label conjugates capable of reacting with the
Abstract: The invention relates to a one-step chemical composition that preserves animal tissue, cells, and biomolecules, such as human tissue, human cells, and biomolecules therein. It improves the fidelity and morphologic structure of cells, organelles, and nuclear chromatin, and maintains and enhances the cellular antigenicity for immunohistochemistry and flow cytometry, while preserving proteins, post-translational modifications of proteins, and nucleic acids. In one embodiment, the composition comprises a) a non-aldehyde precipitating fixative at a concentration below 25% (volume/volume), b) a reversible/cleavable protein cross-linker that targets lipid-associated molecules, and c) a c reversible/cleavable protein cross-linker that targets water soluble molecules. In another embodiment, the composition further includes a kinase inhibitor, a phosphatase inhibitor, and a permeation enhancer.
Type:
Application
Filed:
January 25, 2011
Publication date:
May 30, 2013
Applicant:
GEORGE MASON INTELLECTUAL PROPERTIES, INC.
Inventors:
Virginia A. Espina, Lance A. Liotta, Claudius Mueller
Abstract: A non-invasive method for measuring a bowel inflammatory condition in humans through the presence of HMGB1 protein in fecal extracts and the involvement of such protein in the pathogenesis of chronic inflammatory bowel diseases, more specifically of Crohn's Disease (CD) and of ulcerative colitis (UC), including an analysis protocol to detect the HMGB1 presence in feces through Western blot assay or ELISA assay using an appropriate antigen-antibody. The invention also includes the colorimetric kit for implementing such a method.
Type:
Application
Filed:
August 1, 2011
Publication date:
May 30, 2013
Applicant:
D.M.G. ITALIA SRL
Inventors:
Salvatore Cucchiara, Laura Stronati, Roberta Vitali
Abstract: The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer.
Abstract: The present invention provides a biosensor cartridge (11) comprising a bottom portion (1) with a well (2) adapted to accommodate a liquid sample and a cover portion (3) for closing said well (2). The well (2) has a sensor surface (4). The bottom portion (1) is adapted for allowing light to enter along a first optical path (5), to be reflected at the sensor surface (4) and to exit along a second optical path (6). The invention further relates to a method of manufacturing such a cartridge (11).
Abstract: Disclosed are procedures and methods for diagnosing latent and active cancers in a subject. The described methods include the use of sandwich ELISA assays containing antibodies specific for certain epitopes on the A-protein. This enables the assay to discriminate between the monomelic and homopolymeric forms of A-protein.
Abstract: A composition of matter for use in an immunoassay devices and method comprising a signal antibody, e.g., FAB fragment, covalently linked to a first nucleotide; and one or more signal elements, e.g., signal enzymes such as ALP or fluorescent dyes, each covalently linked to a second nucleotide, wherein the first nucleotide has one or more repeated sequences, and the second nucleotide is bound to one of the one or more repeated sequences on said first nucleotide, and wherein the ratio of the signal antibody to the signal element is controlled by the number of repeated sequences.
Type:
Grant
Filed:
December 30, 2009
Date of Patent:
May 21, 2013
Assignee:
Abbott Point of Care Inc.
Inventors:
Gordon Bruce Collier, Cary James Miller
Abstract: The present invention relates to the identification and use of diagnostic markers for ischemic stroke of the lacunar subtype. The invention relates to devices and kits for performing these methods.
Type:
Application
Filed:
July 28, 2011
Publication date:
May 16, 2013
Applicants:
Institut de recerca Hoepital Universitari Vall D'Heerbron, Fundacio Privada, ABBOTT GMBH & CO. KG
Inventors:
Ingo Curdt, Stuart Blincko, Jens Dhein, Viswanath Devanarayan, Joan Montaner Villalonga
Abstract: An exemplary embodiment may be directed to a fluorescence polarization assay that screens compounds or agents for their affinity to hematopoietic prostaglandin D synthase (H-PGDS) based on their ability to displace a fluorophore-containing detection analyte bound to an enzyme comprising the primary amino acid sequence of H-PGDS. Another exemplary embodiment utilizes an enzyme having a maltose binding protein amino-acid sequence fused with an N-terminus of the enzyme.
Type:
Grant
Filed:
May 13, 2009
Date of Patent:
May 14, 2013
Assignee:
Cayman Chemical Company, Incorporated
Inventors:
Nisha Palackal, Jeffrey K. Johnson, Karie L. McGowan, Kirk W. Maxey, Gregory W. Endres
Abstract: The present invention provides a method of detecting CIP2A protein in a bladder tissue. Methods and compositions are provided herein for detecting and diagnosing bladder cancer by obtaining a bladder tissue from a human subject suspected of bladder cancer, followed by detecting CIP2A protein or mRNA levels in the bladder tissue using Western blot analysis or ELISA to specifically detect CIP2A protein or qRT-PCR to specifically detect CIP2A mRNA. The present method permits specific detection of CIP2A protein or mRNA in bladder tissue as a biomarker for bladder cancer in humans.
Abstract: Embodiments relate generally to an automated multiplex immunoassay for qualitatively and/or quantitatively detecting a plurality of targets on a tissue sample. Kits and apparatuses for practicing such assays are also provided.
Abstract: Embodiments of substrates and processes for chromogenic detection, and in particular pyrazolyl dihydrogen phosphate compounds, are disclosed.
Type:
Application
Filed:
August 12, 2011
Publication date:
May 9, 2013
Applicant:
Ventana Medical Systems, Inc.
Inventors:
Brian Daniel Kelly, Christopher Bieniarz, Hiro Nitta, Fabien Gaire
Abstract: The present application relates to a method of characterizing an agent's ability to increase insulin secretion in a subject. The method comprises determining whether the agent is able to modulate MAG level at the inner surface of the cytoplasmic membrane of a cell and/or ABHD6 activity. The agent is characterized as having the ability to increase insulin secretion in the subject when it is capable of upregulating MAG level at the inner surface of the cytoplasmic membrane and/or downregulating ABHD6 activity.
Type:
Application
Filed:
May 12, 2011
Publication date:
May 9, 2013
Applicant:
VAL-CHUM, LIMITED PARTNERSHIP
Inventors:
Murthy Madiraju, Marc Prentki, Érik Joly
Abstract: A method of detecting MSDX Complex-1, the method introducing a first antibody to a sample to create an antibody-sample mixture, wherein the first antibody is specific for one of fibrinogen, fibronectin, or fibulin-1, the first antibody having a label molecule; providing a well coated with a second antibody, the second antibody is specific for one of fibrinogen, fibronectin, or fibulin-1; introducing the antibody-sample mixture to the well; and introducing a substrate to the antibody-sample mixture in the well, wherein the label molecule and the substrate interact to provide a signal, wherein when the signal is detected then MSDX Complex-1 is detected.
Abstract: The present invention relates to a method for sensitizing a disease cell expressing the epidermal growth factor receptor (EGFR) to a tyrosine kinase inhibitor selective or specific for EGFR and/or its signalling pathway, the method comprising contacting the cell with a miR-7 miRNA, a precursor or variant thereof, or a miRNA comprising a seed region comprising the sequence GGAAGA.
Type:
Application
Filed:
November 24, 2010
Publication date:
May 9, 2013
Inventors:
Peter Jeffery Leedman, Keith Michael Giles, Felicity Caris Kalinowski
Abstract: Provided are a prophylactic and therapeutic agent for amyotrophic lateral sclerosis containing an HMG-CoA reductase inhibitor and a method of screening for a prophylactic and therapeutic drug for amyotrophic lateral sclerosis using an induced pluripotent stem cell derived from a patient with amyotrophic lateral sclerosis.
Abstract: A highly sensitive method of assaying an analyte present in a sample using protamine is provided, as well as an immunoassay reagent and biosensor that reduces non-specific binding by electrostatic interaction of protamine with fibrinogen present in the sample.
Type:
Application
Filed:
April 24, 2012
Publication date:
May 9, 2013
Applicant:
SAMSUNG ELECTRONICS CO., LTD.
Inventors:
Joon Hyung LEE, Soo Suk LEE, Youn Suk CHOI, Jin Young PARK, Hye Jung SEO, Jung Nam LEE, Kyung Yeon HAN
Abstract: Embodiments of hapten conjugates including a hapten, an optional linker, and a peroxidase-activatable aryl moiety are disclosed. In some embodiments, the peroxidase-activatable aryl moiety is tyramine or a tyramine derivative. Embodiments of methods for making and using the hapten conjugates also are disclosed. In particular embodiments, the hapten conjugates are used in a signal amplification assay. In certain embodiments, the hapten is an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an azoaryl, a benzodiazepine, or 7-diethylamino-3-carboxycoumarin. The hapten is coupled to the peroxidase-activatable aryl moiety directly or indirectly via a linker. In certain embodiments, the hapten conjugates are used in multiplexed assays.
Type:
Application
Filed:
July 1, 2011
Publication date:
May 2, 2013
Inventors:
Adrian E. Murillo, Jerome W. Kosmeder, Eric May, William Day, Mark Lefever, Anne M. Pedata, Christopher Bieniarz, Phillip Miller
Abstract: The invention provides novel methods of enhancing axonal regeneration. The methods of the invention are suitable for use in treating a subject suffering from a nerve injury.
Abstract: A reagent for detecting an analyte by a redox reaction and a fluorimetric determination is disclosed. The reagent comprises a compound of formula (I): wherein R1 and R2 are each independently selected from R, (CH2CH2O)mR, COR, COOR, and OCOR; each R3 is independently selected from NO2, CN, R, OR, OCOR, COOR, SR, and halogen; R is H or C1-C4 alkyl, where alkyl is optionally substituted with one or more functional group independently selected from the group consisting of halogen, OR, SR, NR2, COOR, CONR2, SO3R and salts thereof, and PO(OR)3 and salts thereof; m is an integer from 1 to 20; and n is 1, 2, or 3. The reagent may further comprise an enzyme or a coenzyme for reducing or oxidizing an analyte.
Type:
Grant
Filed:
April 9, 2010
Date of Patent:
April 30, 2013
Assignee:
Roche Diagnostics Operations, Inc.
Inventors:
Carina Horn, Joachim Hoenes, Jürgen Spinke
Abstract: This invention provides a immunochromatography detection device that can detect PBP2? produced specifically by a bacterium of multidrug-resistant staphylococcus with high sensitivity in a simple and rapid manner via immunochromatography detection to determine infection with multidrug-resistant staphylococcus, a diagnostic method using such detection device, and a diagnostic kit comprising such detection device.
Abstract: Point-of-care assays for quantitatively measuring the amount of small analytes, such as opioids, tetrahydrocannibinol (“THC”), or hormones, in a biological sample are disclosed. The assays are capable of non-competitive detection of a small analyte using binding agents that selectively bind the analyte and capture agents that selectively bind a complex of the binding agent and analyte but do not bind either free binding agent or free analyte. The assay is capable of simultaneous diction of multiple analytes for multiplex analysis and quantitative control. Quantitative measurements are obtained by plotting results against a response surface calculated from a plurality of analyte standards and adjusted using internal controls.
Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
Type:
Application
Filed:
September 28, 2012
Publication date:
April 25, 2013
Applicants:
Board of Regents, The University of Texas System, Millennium Pharmaceuticals, Inc.
Inventors:
Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System
Abstract: The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis.
Type:
Application
Filed:
September 14, 2012
Publication date:
April 25, 2013
Applicant:
National Defense Medical Center
Inventors:
Ann Chen, Shuk-Man Ka, Chao-Wen Cheng, Jenn-Han Chen, Chen-Wen Yao